The NASDAQ capitals markets, how suitable are they for your organisation?




Episode Loading...




PharmaTelevision requires Javascript enabled and Adobe Flash Player to watch our programmes. If you do not have Flash installed, you can download it for free from the Adobe Flash homepage.

Improve your Internet experience and start watching exciting new video content.

Video title: The NASDAQ capitals markets, how suitable are they for your organisation?
Released on: October 07, 2015. © PharmaVentures Ltd
Share/save this page:
Email
Bookmark
Facebook
Twitter
LinkedIn
Follow us:
RSS
Twitter
In This Episode:
    Adam Korstyal, Senior Vice President, NASDAQ, speaks to Fintan Walton, CEO of PharmaVentures, about the benefits of listing a Biotech company on the NASDAQ stock exchange.
  • Summary
  • Transcript
  • Participants
  • Company
Adam Korstyal, Senior Vice President, NASDAQ, speaks to Fintan Walton, CEO of PharmaVentures, about the benefits of listing a Biotech company on the NASDAQ stock exchange. They distinguish between NASDAQ First North, NASDAQ North West and the main NASDAQ Market in the USA. They give insight on the kinds of preparation Biotech companies should make when considering launching an IPO.
Adam Korstyal, Senior Vice President, NASDAQ, speaks to Fintan Walton, CEO of PharmaVentures, about the benefits of listing a Biotech company on the NASDAQ stock exchange. They distinguish between NASDAQ First North, NASDAQ North West and the main NASDAQ Market in the USA. They give insight on the kinds of preparation Biotech companies should make when considering launching an IPO.
Adam Kostyál is Senior Vice President of Listing Services, Europe. In addition to Nasdaq Nordic Exchanges, where there are more than 800 companies listed, Adam is also responsible for the more than 120 European companies that are either primarily listed or dual listed on the Nasdaq Stock Market in the U.S. Adam has been with Nasdaq for the past 10 years. He started his career at OMX as a Sales Director, and then became Head of the Strategic Initiative Groups in 2006. Most recently, Adam was Vice President of Market Technology Sales responsible for sales, account management, and business development for the Eastern and Western Europe. Prior to Nasdaq, Adam held various positions with Enron, Cell Network and Bloomberg. He holds a BSc in Economics and Marketing from Vrije Universiteit de Bruxelles and speaks four languages including English, Swedish, Italian and French.
http://www.nasdaq.com/